when does semaglutide go off patent Off-patent in 2026: the next revolution in anti-obesity medications As the patent for semaglutide,

Many patients report losing up to 15% of their body weight over time, making it a powerful option for those struggling with obesity

SURMOUNT-5, the most anticipated trial, will compare tirzepatide to a GLP-1 agonist approved for the treatment of obesity in obese or overweight patients ( without type 2 diabetes) with weight-related co-morbidities

Children aged 6 -12 who got less than 10 hours of sleep a night showed 3.5 times greater incidence of obesity than those who got 12 hours of sleep

Tirzepatide's greater potency can mean more noticeable results as you reach higher doses, but both require patience through the early titration weeks

Switching from Semaglutide to Tirzepatide FAQs Do I need a washout period when switching from semaglutide to tirzepatide